NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

Members Present: Stacy Ramirez, PharmD; Bill Origer, MD; Mark Helm, MD; Cat Livingston, MD; Tim Langford, PharmD; Robin Moody, MPH; Russ Huffman, PMHNP; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Deborah Weston, JD; Jessica Ickes, MPA; Liz Stuart, MPH

Audience: Amy Burns, AllCare CCO; Brandie Feger, Advanced Health CCO; Georgette Dzwilewsk, Indivior; Janine Fournier, Jason Kniffin; Jim Slater, CareOregon; Kevin Gallagher, Fennec Pharmaceuticals; Lori McDermott, Viking HCS; Marc Rueckert, Argenx; Mark Kantor, AllCare CCO; Matt Metcalf, CSL Vifor; Melissa Snider, Gilead; Michael Foster, BMS; Norm Navarro, Providence Health Plan; Rick Frees, Vertex Pharmaceutical; Rochelle Yang, Teva; Saghi Maleki, Takeda Pharmaceuticals; Sydney Thomas, AllCare/APPE student; Tiffany Jones, Pacificsource; Tiina Andrews, UHA; Tom Telly, Supernus; Andrea Willcuts; Idorsia

I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and October 2022 Minutes presented by Roger Citron
   ACTION: Motion to approve, 2nd, all in favor with one abstention
D. Department Update provided by Andrew Gibler, PharmD
E. Recognition of Dr. Helm provided by Trevor Douglass, DC

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Report
B. Oncology Prior Authorization (PA) Updates  
   Recommendation:
   - Add: Lytgobi® (futibatinib); Tecvayli™ (teclistamab-cqyv); and Imjudo® (tremelimumab) to Table 1 in the Oncology Agents prior authorization (PA) criteria
C. Orphan Drug Policy Updates  
   Recommendation:
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Pedmark® (sodium thiosulfate) based on FDA-approved labeling
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Lan Starkweather, PharmD
B. RetroDUR Report: Dave Engen, PharmD
C. Oregon State Drug Review: Kathy Sentena, PharmD  
   - Asthma Guidance Update with a Focus on Changes for Managing Patients with Mild Asthma  
   - Population Trends in the Use of Migraine Preventative Treatments  
   ACTION: Motion to approve, 2nd, all in favor

IV. DUR NEW BUSINESS

A. Polypharmacy Drug Utilization Evaluation: Dave Engen, PharmD  
   Recommendation:
   - No policy changes are recommended  
   ACTION: Motion to approve, 2nd, all in favor

B. Early Periodic Screening, Diagnostic and Treatment (EPSDT) Program PA Criteria Update: Sara Fletcher, PharmD; Jessica Ickes, MPA; Liz Stuart, MPH  
   Recommendations:
- Update all PA criteria to support individualized review for members younger than 21 years of age who have an unfunded diagnosis, to evaluate whether medically appropriate and necessary
- In the absence of more specific criteria already approved by P&T, standard definitions for medically appropriate and necessary use will include:
  - FDA-approved or compendia-supported indication;
  - Trial and failure, contraindication, or intolerance to at least 2 preferred products (when available in the class);
  - and Documentation that the disease is of sufficient severity that it impacts the patient’s health

**ACTION:** Motion to approve, 2nd, all in favor

---

**V. DUR OLD BUSINESS**

A. **Sedatives PA Criteria Update:** Sarah Servid, PharmD

**Recommendations:**
- Update PA criteria to limit sedative use to 30 days and encourage use of cognitive behavioral therapy for insomnia.

**ACTION:** The Committee recommended adding language regarding the member being unable to access such therapy and to explore options to auto-approve a short-term supply

**Motion to approve, 2nd, all in favor**

---

**VI. PREFERRED DRUG LIST NEW BUSINESS**

A. **Growth Hormone PA Criteria Update:** Dave Engen, PharmD

**Recommendations:**
- Update the growth hormone PA criteria to align with HERC coverage guidance and FDA-approved indications
- Evaluate costs in executive session

**ACTION:** Motion to approve, 2nd, all in favor

---

B. **Drugs for Asthma/COPD Class Update:** Kathy Sentena, PharmD

**Recommendations:**
- No Preferred Drug List (PDL) changes recommended based on review of recently published evidence
- Update PA criteria to align with current guidelines
- Retire ICS/LABA specific criteria and subject non-preferred therapies to general PA criteria for non-preferred products
- Evaluate costs in executive session

**ACTION:** Motion to approve, 2nd, all in favor

---

**C. Influenza Class Update:** Sara Fletcher, PharmD

**Recommendations:**
- No PDL changes recommended based on review of recently published evidence
- Update PA criteria with expanded indications and age ranges for peramivir and baloxavir
- Evaluate costs in executive session

**ACTION:** Motion to approve, 2nd, all in favor

---

**D. Topical Products for Inflammatory Skin Conditions Class Update and New Drug Evaluations:** Deanna Moretz, PharmD

**Recommendations:**
- Update PA criteria to include use of ruxolitinib in patients 12 years and older, meeting HERC guidance for severe nonsegmental vitiligo, or having hand, foot, face, or mucous membrane involvement
- Designate roflumilast and tapinarof non-preferred on the PDL and subject to the PA criteria limiting use to:
  - Individuals meeting HERC guidance for severe plaque psoriasis or those having hand, foot, face, or mucous membrane involvement and,
  - FDA-approved ages and,
  - History of inadequate response to at least 2 moderate-to-high potency topical corticosteroids for at least 4 weeks
- Update PA criteria to remove PA for preferred products and accommodate individual review under EPSDT
- Combine the “Topical Anti-Psoriatic” class in with the “Topical Agents for Inflammatory Skin Conditions” class
- Evaluate costs in Executive Session

**ACTION:** Motion to approve, 2nd, all in favor
Members Present: Stacy Ramirez, PharmD; Bill Origer, MD; Mark Helm, MD; Tim Langford, PharmD; Robin Moody, MPH; Russ Huffman, PMHNP; Eddie Saito, PharmD

Staff Present: Sarah Servid, PharmD; Deanna Moretz, PharmD; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD

VIII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Growth Hormone PA Criteria Update
   Recommendation: Make Nutropin AQ® Nuspin non-preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

B. Drugs for Asthma/COPD Class Update
   Recommendations: Make Combivent Respimat® non-preferred and Spiriva Respimat® preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

C. Influenza Class Update
   Recommendations: Make no changes to the PDL
   ACTION: Motion to approve, 2nd, all in favor

D. Topical Products for Inflammatory Skin Conditions Class Update and New Drug Evaluations
   Recommendations: Make tazarotene gel non-preferred on the PDL
   ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN